About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 50 record(s)
Req # A-2020-18436
Provide a detailed disclosure of all third parties consultations over regulation and pricing of new drugs from June 1, 2019 to November 19, 2020, broken down by date, meeting minutes, and summary of meetings.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2020-18440
Copies of all reports, email exchanges, memos, briefing notes, PowerPoints and other similar documents regarding the regulatory process of the United States Food and Drug Administration and the European Union's Medicines Agency compared to the PMPRB guidelines from June 1, 2019 to November 19, 2020.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-00810
Copies of all emails to/from and cc'ing Douglas Clark on the excessive prices penalty from January 1, 2019 to January 18, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-00812
The daily calendar of meetings, calls and other taskings for Douglas Clark from June 1, 2019 to January 18, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-00815
Copies of all emails to/from cc'ing Guillaume Coullaird regarding the use of the excessive prices penalty and future use against pharmaceutical companies from January 1, 2019 to January 18, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-01073
Copies of all emails to/from and cc'ing Douglas Clark, Mitchell Levine and Melanie Bourassa-Forcier regarding the decision to delay the implementation of the PMPRB guidelines to Summer 2021 from November 1, 2020 to January 20, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-01083
Copies of all emails to/from and cc'ing Douglas Clark, Mitchell Levine and Melanie Bourassa-Forcier regarding any directives from the Health minister's office regarding the implementation of the new PMPRB guidelines from January 1, 2020 to January 20, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2020-00004
List of mandatory or voluntary training, info sessions, awareness sessions, and sensitivity training from January 1, 2020 to September 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-04135
Copies of the Human Drug Advisory (HDAP) report for erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-09098
Copies of all records discussing the impacts of the regulatory changes to the PMPRB from August 2019 until August 2020. Copies of all correspondence from all pharmaceutical companies expressing their concerns with the changes and any responses back to these companies. Copies of all correspondence from all advocating groups expressing concerns with the changes and any responses back to these groups. Copies of all correspondence between departmental staff discussing the impacts of the regulatory changes to the PMPRB. Copies of all records discussing the impacts of the PMPRB changes on individuals living with rare diseases. Copies of all correspondence from Vertex Pharmaceuticals relating to Kalydeco, Orkambi, Symdeko, and Trikafta. Copies of all correspondence between government officials (Prime Minister, Ministers, all members of parliament, constituency staff, deputies, assistant deputies, directors, managers, supervisors, staff, and any other employee of the Government of Canada relating to the PMPRB regulatory changes. Copies of all presentations relating to the PMPRB regulatory changes.Organization: Patented Medicine Prices Review Board Canada
September 2020